Welcome to MutualFunds.com. Please help us personalize your experience.
Your personalized experience is almost ready.
Check your email and confirm your subscription to complete your personalized experience.
Thank you for your submission, we hope you enjoy your experience
Shauna O'Brien Dec 22, 2014
Gilead shares are pulling back significantly on today’s news. The only argument that Gilead could have is that today’s announcement limits patients’ options for treatment.
This is a very important event for biotech investors to be aware of since there could be similar moves in the near future, which can impact other biotech companies. If Express Scripts is saving by choosing the cheaper option, its peers including CVS Health (CVS), Aetna (AET) and UnitedHealth (UNH) could follow suit.
It is hard to say if investors should head for the exits on today’s biotech-related headlines. Considering the sector has had consecutive 50% gains, some profit-taking is likely in the cards.
|VTSMX||Vanguard Total Stock Mkt Idx||1.37%|
|VFINX||Vanguard 500 Index||1.28%|
Shares of GILD are up 28% YTD.
Subscribe to receive FREE updates, insigns, and more, straight to your inbox